Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human Phase I trial assessing safety, tolerability and immunomodulatory effects of Foralumab in healthy volunteers

Trial Profile

A first-in-human Phase I trial assessing safety, tolerability and immunomodulatory effects of Foralumab in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2018

At a glance

  • Drugs Foralumab (Primary)
  • Indications Amyotrophic lateral sclerosis; Multiple sclerosis; Neurodegenerative disorders
  • Focus Adverse reactions; First in man; Proof of concept
  • Most Recent Events

    • 24 Sep 2018 According to a Tiziana Life Sciences media release, this is a single-site study and will be conducted at the Brigham and Womens Hospital (BWH).
    • 24 Sep 2018 According to a Tiziana Life Sciences media release, the US FDA has approved the IND application made in collaboration with the Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts to initiate this study and will commence dosing the patients by Nov 2018.
    • 04 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top